Evidence map›Paper›PMID 38839347›Full record

ArticleThe Journal of veterinary medical science2024

α7 nicotinic acetylcholine receptor agonist attenuates allergen-induced immediate nasal response in murine model of allergic rhinitis.

Shuhei Yamashita, Kento Miura, Anna Matsuura, Norimasa Yamasaki, Naoto Uda, Sawako Ogata, Naohisa Hosomi, Shotaro Nakajima, Noriko Kitamura, Minoru Gotoh and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of veterinary medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuhei YamashitaDepartment of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Kento MiuraDepartment of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Anna MatsuuraDepartment of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Norimasa YamasakiDepartment of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Naoto UdaDepartment of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Sawako OgataDepartment of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Naohisa HosomiDepartment of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Shotaro NakajimaDepartments of Multidisciplinary Treatment of Cancer and Regional Medical Support, Fukushima Medical University School of Medicine, Fukushima, Japan.
Noriko KitamuraNeurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Minoru GotohDepartment of Otorhinolaryngology, Nippon Medical School, Tokyo, Japan.
Akio MoriClinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan.
Osamu KaminumaDepartment of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of nicotinic acetylcholine receptor (nAChR) subunits on various immune cells suggests their involvement in allergic rhinitis. However, how exactly they contribute to this pathogenesis is not yet confirmed. Our present study examined the therapeutic potential of GTS-21, an α7 nAChR agonist, for treating allergic rhinitis by employing its mouse models. GTS-21 treatment reduced allergen-induced immediate nasal response in ovalbumin (OVA)-sensitized model. However, nasal hyperresponsiveness or eosinophil infiltration elicited in either the OVA-sensitized or T helper 2 cell-transplanted model was not affected by GTS-21. GTS-21 did not alter allergen-induced passive cutaneous anaphylaxis response in anti-dinitrophenyl IgE-sensitized mice. This evidence implies GTS-21's potential to alleviate allergic rhinitis without perturbing T cells or mast cells.

Indexed as

Allergensalpha7 Nicotinic Acetylcholine ReceptorOvalbuminRhinitis, AllergicAnimalsBenzylidene CompoundsDisease Models, AnimalFemaleMiceMice, Inbred BALB CNicotinic AgonistsPyridines3-(2,4-dimethoxybenzylidene)anabaseineAllergensalpha7 Nicotinic Acetylcholine ReceptorBenzylidene CompoundsNicotinic AgonistsOvalbuminPyridinesallergic rhinitismurine modelα7 nicotinic acetylcholine receptor

Identifiers

PMID38839347
PMCPMC11251814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.